August 2012

The Australia Research Council (ARC) has awarded a $370,000 Linkage grant to Paul Young, Daniela Traini, and Brian Oliver of RespiTech and the cell biology group at the Woolcock Institute of Medical Research (WIMR) for… Read more . . .

Israeli phamaceutical company Kamada Ltd announced that it has received Russian and Australian patents related to its inhaled alpha-1 antitrypsin (AAT) for the treatment of lung diseases. Russian Patent No. 2472524 is titled “Alpha-1 Antitrypsin… Read more . . .

Civitas Therapeutics has received a $1 million grant from The Michael J. Fox Foundation for Parkinson’s Research for development of CVT-301 inhaled L-dopa for the treatment of motor fluctuations in Parkinson’s disease patients, the company… Read more . . .

Teva has announced that it will acquire inhaled drug developer MicroDose Therapeutx for $40 million up front plus up to $125 million in development and regulatory milestone payments, as well as sales milestone payments and… Read more . . .

Shareholders of Elan Corporation have rejected the company’s $1 billion deal for royalties from Theravance inhaled drugs, including the Breo and Anoro Ellipta DPIs. Anticipating the result from the Theravance vote, Elan announced on June… Read more . . .

So many shareholders have already voted against Elan’s proposed $1 billion deal for royalties from Theravance inhaled drug products, says Royalty Pharma, that the proposal is unlikely to pass at the upcoming meeting of Elan… Read more . . .